Details for: REVOLADE
Company: NOVARTIS PHARMACEUTICALS CANADA INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02361825 | REVOLADE | ELTROMBOPAG (ELTROMBOPAG OLAMINE) | 25 MG | TABLET | ORAL |
| 02361833 | REVOLADE | ELTROMBOPAG (ELTROMBOPAG OLAMINE) | 50 MG | TABLET | ORAL |
Summary Reports
Summary Basis of Decision
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - REVOLADE (eltrombopag) - Serious Skin Reactions
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Regulatory Decision Summary
Summary Safety Review - REVOLADE (eltrombopag) - Serious Skin Reactions
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.